- Quotes
- Dashboard
- Chart
- Historical Prices
- Options
- Analysis
- Focus Articles
- Related Articles1 new
- Instablogs
- StockTalks
- News & PR
- News
- Market Currents
- Press Releases
- Coverage
- Cramer
- Top Analysts
- Business Intelligence
- Transcripts
- Events
- Key Developments
- Earnings
- History & Projected
- Consensus
- Peer Earnings
- Filings
- SEC Filings
- Annual Report
- Financials
- Income Statement
- Balance Sheet
- Cash Flow
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
QCOR Market Currents
more »
-
April 24 Questcor Pharmaceuticals (QCOR): Q1 EPS of $0.58 beats by $0.06. Revenue of $96M (+161% Y/Y) beats by $9M. Shares +0.9% AH. (PR)
2 Comments[Earnings, Healthcare]
QCOR in Focus
more »
QCOR Related Articles
more »
QCOR News
more »
-
at MarketWatch.com (Feb 22, 2012)
-
at CNBC.com (Feb 13, 2012)
-
at CNBC.com (Nov 17, 2011)
-
at MarketWatch.com (Oct 26, 2011)
-
at MarketWatch.com (Oct 13, 2011)
QCOR Press Releases and Filings
more »
-
PR Newswire (Thu, 11:58AM)
-
PR Newswire (May 16, 2012)
-
PR Newswire (May 7, 2012)
-
PR Newswire (Apr 24, 2012)
-
PR Newswire (Apr 10, 2012)
QCOR Latest Transcript
more »
-
Wed, May 16Popular searches: transcript.
QCOR Cramer
more »
QCOR Instablog posts
more »
QCOR vs. ETF Alternatives
Company Description
We market H.P. Acthar® Gel (repository corticotropin injection), an injectable drug that is approved for the treatment of certain disorders with an inflammatory component, including the treatment of exacerbations associated with multiple sclerosis (“MS”), and the treatment of nephrotic syndrome.... More
